Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Allergan Evaluates Bids for its Lap-Band Weight Loss Product

May 1 (Bloomberg) -- Allergan Inc., the maker of the Botox wrinkle treatment, said it is evaluating offers for the company’s Lap-Band weight loss product and the rest of the obesity-treatment unit.

The Botox maker, which reclassified the obesity unit as a discontinued operation in February, reiterated today in a statement that it anticipates a signed agreement by the middle of 2013. Chief Executive Officer David Pyott in January said he wanted to sell the business by the end of the first quarter as demand for the weight-loss surgery plummeted and safety questions soared.

The discontinued business, which once generated a third of the company’s U.S. sales, posted earnings of $400,000 during the first quarter, down from $1.9 million a year earlier, the Irvine, California-based company said. Allergan took a $346.2 million pretax charge in the first quarter to write down the obesity unit assets to their estimated fair value, less the cost to sell them.

Allergan fell 5.6 percent to $107.23 at 11 a.m. in New York. The shares had risen 18 percent in the past 12 months through yesterday.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.